Pembrolizumab, another ICI, was compared to docetaxel in the Keynote-010 trial in patients with metastatic NSCLC who had received at least one line of chemotherapy and had a PD-L1 expression level of 1% or higher [8]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.